FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Alemtuzumab Better than Interferon in MS


























Image Source: BOURNEMOUTHPHYSIOTHERAPY

Alemtuzumab provided more benefits to patients with relapsing remitting multiple sclerosis (RRMS) who had poor response to other therapies than subcutaneous interferon-B-1a (SC IFN-B-1a) provided, according to the results of a recent study. Conducted by Gavin Giovannoni, MD, PhD, of Queen Mary University of London, and colleagues, the study was published in the journal Neurology on October 12, 2016.

The authors begin by discussing the fact that limiting disability is an important part of caring for patients with MS, but that interest is increasing in not only limiting disability but in helping patients with disability improve. They say, “Interest is growing in aiming for confirmed disability improvement (CDI), a higher standard for therapeutic efficacy than merely slowing disability accumulation.” In pursuit of that goal, the researchers say the aim of the present study was “to characterize effects of alemtuzumab treatment on measures of disability improvement in patients with  multiple sclerosis with inadequate response to prior therapy.”   

The researchers used information from the phase 3 trial called Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II (CARE-MS II), as well as the Expanded Disability Status Scale (EDSS) and some -EDSS-based methods for measuring disability to determine  to CDI.   

Alemtuzumab was more effective than SC IFN-B1a at improving disability outcomes,” report the researchers, both reducing the risk of disability worsening and also increasing CDI at 6-months. “The current analysis demonstrates  in patients with RRMS with an inadequate response to prior DMTs [disease modifying therapies] alemtuzumab provides greater recovery of function across several disability measures than SC IFN-B-1a,” say the authors.   

Nearly half of the 426 patients taking alemtuzumab in the CARE-MS II study showed improvement as measured by the EDSS, in all 7 functional domains, leading the researchers to say the results “suggest that such disabilities may often be reversible (at least partially) in patients with active RRMS if they receive suitable therapy, irrespective of the type of baseline functional deficit.” 

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News